Phase II trial of neoadjuvant osimertinib for surgically resectable <i>EGFR</i>-mutated non-small cell lung cancer.
Jacqueline V. Aredo(Stanford University), Collin M. Blakely(City College of San Francisco), Greg M. Allen(University of California, San Francisco), Claire K. Mulvey(University of California, San Francisco), Tejas Patil(Sidney Kimmel Comprehensive Cancer Center), Anatoly Urisman(City College of San Francisco), Bianca Bacaltos(University of California, San Francisco), Dara L. Aisner(University of Colorado System), Johannes R. Kratz(University of California, San Francisco), Matthew A. Gubens(University of California, San Francisco), Kirk D. Jones, Erin L. Schenk(University of Colorado Anschutz Medical Campus), Jonathan W. Riess(University of California Davis Medical Center), Turja Chakrabarti(University of California, San Francisco), D. Lucas Kerr(UCSF Helen Diller Family Comprehensive Cancer Center), David M. Jablons(City College of San Francisco), Melissa H. Coleman(University of California, San Francisco), Trever G. Bivona(University of California, San Francisco), Megan Gee(University of California, San Francisco), Julia Rotow(University of California, San Francisco)
Cited by 23
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2019|1k